Global Point of Care Molecular Diagnostics Market Statistics: USD 8.7 Billion Value by 2033
Summary:
- The global point of care molecular diagnostics market size reached USD 4.0 Billion in 2024.
- The market is expected to reach USD 8.7 Billion by 2033, exhibiting a growth rate (CAGR) of 8.78% during 2025-2033.
- North America leads the market, accounting for the largest point of care molecular diagnostics market share.
- Assays and kits exhibit a clear dominance in the market due to their essential role in facilitating rapid, accurate, and easy-to-use testing in POC settings.
- Polymerase chain reaction (PCR) represents the largest segment because of its high sensitivity, specificity, and widespread use in detecting a broad range of pathogens in POC diagnostics.
- Wet anaerobic digestion remains a dominant segment in the market, allowing for better methane production and more consistent energy generation.
- The rising incidence of infectious diseases globally is driving the need for point of care (POC) diagnostic services.
- Ongoing advancements, particularly in the miniaturization of molecular diagnostic devices, are propelling the growth of the market.
Industry Trends and Drivers:
- Increasing Prevalence of Infectious Diseases:
This global ailment frequency demands for POC diagnostics is on the rise and so the market. Communicable illnesses including influenza and tuberculosis require a diagnosis to allow treatment, if at all there is a chance later and this is actualising POC testing. It is very different from conventional lab procedures in the sense that one gets POC molecular diagnostics within one hour to enable clinical decisions. This rate is useful in managing the spread of the disease and also the improvement of the patient results. Similarly, molecular diagnostics offer tests that, unlike traditional laboratory testing, do not need to be performed in specialized laboratories at the point of care to effectively address diseases including those leading to improved infectious disease control in perhaps inaccessible or economically disadvantaged areas. Hence, rapid POC molecular diagnostics is a current broad utilisation strategy among the healthcare providers for the diagnosis of the diseases.
- Technological Advancements and Miniaturization:
Current innovations are being propelled by expansion that is especially driven by development of molecular diagnostic devices. Every day new technologies such as microfluidics, lab-on-chip, smart phone apps, point of care PCR facililities make it easier to develop small, easy to use POC diagnostic kits. The level of performance allowed by these devices is similar to the one that a clinical laboratory equipment is capable of achieving with molecular tests. The beauty of these devices is that the diagnostic test can be done right from the patient side, right from the clinic or from anywhere. That advancement in technology is also making molecular diagnostics more portable to other aspects than just laboratory setting which can embrace its usage.
- Growing Demand for Personalized Medicine:
Personalized medicine is boosting market growth. It tailors treatments to genetics and specific diseases. This approach requires quick, accurate diagnostic tools. Point-of-care (POC) molecular diagnostics meet this need. They quickly detect genetic markers, pathogens, and mutations. This supports the development of personalized treatments. For instance, in cancer care, these tests identify specific mutations. This helps doctors choose the best therapies. Tailored treatments increase effectiveness and reduce risks. This improves patient outcomes. Consequently, the demand for POC molecular diagnostics is rising. It’s driven by the shift towards personalized healthcare and the need for timely, accurate tests.
Request for a sample copy of this report: https://www.imarcgroup.com/point-of-care-molecular-diagnostics-market/requestsample
Point of Care Molecular Diagnostics Market Report Segmentation:
By Product and Services:
- Assays and Kits
- Instruments and Analyzers
- Software and Services
Assays and kits exhibit a clear dominance in the market due to their essential role in facilitating rapid, accurate, and easy-to-use testing in POC settings.
By Technology:
- Polymerase Chain Reaction (PCR)
- Hybridization
- DNA sequencing
- Microarray
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Others
Polymerase chain reaction (PCR) represents the largest segment because of its high sensitivity, specificity, and widespread use in detecting a broad range of pathogens in POC diagnostics.
By Application:
- Infectious Diseases
- Oncology
- Hematology
- Prenatal Testing
- Endocrinology
- Others
Infectious diseases hold the biggest market share as POC molecular diagnostics are crucial for the timely detection and management of these diseases, particularly in outbreak scenarios.
By End User:
- Physicians’ Offices
- Hospitals and ICUs
- Research Institutes
- Others
On the basis of the end user, the market has been segregated into physicians’ offices, hospitals and ICUs, research institutes, and others.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America dominates the market attributed to its advanced healthcare infrastructure, high adoption rates of new technologies, and strong presence of key industry players.
Top Point of Care Molecular Diagnostics Market Leaders:
The point of care molecular diagnostics market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:
- Abbott Laboratories
- Becton Dickinson and Company
- Binx Health Inc.
- Co-Diagnostics Inc.
- F. Hoffmann-La Roche Ltd
- Gene STAT Molecular Diagnostics LLC
- Hemocue AB (Danaher Corporation)
- Meridian Bioscience Inc.
- Molbio Diagnostics Private Limited
- Quidel Corporation
- Siemens Healthcare GmbH (Siemens AG)
- Thermo Fisher Scientific Inc.
- Visby Medical Inc.
Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1–631–791–1145
